Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

320 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia.
Tsimberidou AM, Keating MJ, Jabbour EJ, Ravandi-Kashani F, O'Brien S, Estey E, Bekele N, Plunkett WK Jr, Kantarjian H, Borthakur G. Tsimberidou AM, et al. Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):395-400.e1. doi: 10.1016/j.clml.2014.01.009. Epub 2014 Feb 3. Clin Lymphoma Myeloma Leuk. 2014. PMID: 24637132 Free PMC article. Clinical Trial.
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. Keating MJ, et al. Among authors: plunkett w. J Clin Oncol. 2005 Jun 20;23(18):4079-88. doi: 10.1200/JCO.2005.12.051. Epub 2005 Mar 14. J Clin Oncol. 2005. PMID: 15767648 Clinical Trial.
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Tsimberidou AM, et al. Among authors: plunkett w. J Clin Oncol. 2008 Jan 10;26(2):196-203. doi: 10.1200/JCO.2007.11.8513. J Clin Oncol. 2008. PMID: 18182662 Clinical Trial.
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Jabbour E, et al. Among authors: plunkett w. Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):244-51. doi: 10.1016/j.clml.2012.03.003. Epub 2012 Apr 24. Clin Lymphoma Myeloma Leuk. 2012. PMID: 22534616 Free PMC article. Clinical Trial.
Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.
Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Badoux X, Kantarjian H, Keating MJ; Chronic Lymphocytic Leukemia Research Consortium. Tsimberidou AM, et al. Among authors: plunkett w. Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):568-74. doi: 10.1016/j.clml.2013.03.012. Epub 2013 Jun 27. Clin Lymphoma Myeloma Leuk. 2013. PMID: 23810245 Free PMC article. Clinical Trial.
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. Short NJ, et al. Among authors: plunkett w. Leuk Lymphoma. 2018 Apr;59(4):813-820. doi: 10.1080/10428194.2017.1349907. Epub 2017 Jul 18. Leuk Lymphoma. 2018. PMID: 28718728 Free PMC article. Clinical Trial.
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Jain N, et al. Among authors: plunkett w. Leukemia. 2021 Dec;35(12):3421-3429. doi: 10.1038/s41375-021-01280-8. Epub 2021 May 18. Leukemia. 2021. PMID: 34007049 Clinical Trial.
320 results